Perinatální expozice antivirotikům nepoškozuje vývoj nervové soustavy dítěte (angl.)

 Neurodevelopment is unaffected in children not infected with HIV but
who are exposed perinatally to antiretroviral drugs, according to a
report in the October issue of Pediatrics.

"Benefits from highly active antiretroviral therapy (HAART) in
pregnancy/delivery and the neonate greatly outweigh the risks of HAART
exposure, reducing the mother-to-child HIV transmission rate to less
than 1% to 2% with relatively few known adverse effects," Dr. Ariane
Alimenti told Reuters Health.

Dr. Alimenti from the University of British Columbia, Vancouver, and
colleagues evaluated the early neurodevelopment of 63 HIV-uninfected
children -- 39 born to HIV-infected mothers with perinatal exposure to
HAART, and 24 born to HIV-negative women.

All mean developmental scores tested were lower in the HAART-exposed
group than in the control group, the authors report. After adjustment
for maternal substance use in pregnancy, however, these differences
disappeared.

Maternal substance use was far higher in the HAART-exposed group
(51%) than in the control group (12%), the results indicate, as was
maternal injection drug use (46% versus 4%, respectively).

"Although HAART exposure may lead to mitochondrial toxicity, these
preliminary results suggest that HAART exposure in HIV-negative
children is not associated with altered global measures of development
and behavior at 2 years of age," the team concludes. "However, our
findings do illustrate the importance of accounting for prenatal
substance use, which frequently accompanies prenatal HIV and HAART
exposure."

"It is extremely important that all pregnant women be tested for HIV
in pregnancy so that HIV-positive women can benefit from prevention
measures for mother-to-child transmission," Dr. Alimenti added.

 

Zdroj: Medscape